

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT TO  
SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) February 5, 2026

**TECTON, DICKINSON AND COMPANY**

(Exact Name of Registrant as Specified in Its Charter)

**New Jersey**

(State or Other Jurisdiction of Incorporation)

**001-4802**

(Commission File Number)

**22-0760120**

(IRS Employer Identification No.)

**1 Becton Drive,**

**Franklin Lakes,**

**New Jersey**

**07417-1880**

(Address of Principal Executive Offices)

(Zip Code)

**(201) 847-6800**

(Registrant's Telephone Number, Including Area Code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of Each Class</b>	<b>Trading Symbol</b>	<b>Name of each exchange on which registered</b>
Common stock, par value \$1.00	BDX	New York Stock Exchange
1.900% Notes due December 15, 2026	BDX26	New York Stock Exchange
1.208% Notes due June 4, 2026	BDX/26A	New York Stock Exchange
1.213% Notes due February 12, 2036	BDX/36	New York Stock Exchange
3.519% Notes due February 8, 2031	BDX31	New York Stock Exchange
3.828% Notes due June 7, 2032	BDX32A	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**ITEM 7.01 REGULATION FD DISCLOSURE.**

Effective October 1, 2025, Becton Dickinson and Company ("BD" or the "Company") reorganized its organizational units into five worldwide business segments: BD Medical Essentials ("Medical Essentials"), BD Connected Care ("Connected Care"), BD BioPharma Systems ("BioPharma Systems"), BD Interventional ("Interventional") and BD Life Sciences ("Life Sciences"). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. The segment reorganization did not affect the principal product lines of any organizational unit.

The following table provides an overview of the Company's reportable segments and their respective organizational units.

<b>Reportable Segment:</b>	<b>Organizational Units:</b>
Medical Essentials	Medication Delivery Solutions, Specimen Management
Connected Care	Medication Management Solutions, Advanced Patient Monitoring
BioPharma Systems	BioPharma Systems (formerly Pharmaceutical Systems)
Interventional	Urology and Critical Care, Peripheral Intervention, Surgery
Life Sciences <sup>(1)</sup>	Diagnostic Solutions and Biosciences

(1) On July 13, 2025, the Company entered into a definitive agreement to combine its Biosciences and Diagnostic Solutions business with Waters Corporation. Subsequent to the separation and combination, the Life Sciences segment will be eliminated from the Company's segment reporting, which will consist of the remaining four reportable segments.

In order to assist investors, BD has furnished as Exhibit 99.1 recast historical segment revenues for fiscal year 2025, the quarterly periods within fiscal year 2025, and the corresponding prior year periods to present segment revenues in accordance with the new segment structure.

The information furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles ("non-GAAP measures"). Details regarding these non-GAAP measures and adjustments can be found in the schedules furnished as Exhibit 99.1.

The information contained in this Current Report on Form 8-K and Exhibit 99.1 hereto shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

---

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

Exhibit [99.1](#)

BD Unaudited Historical Recast Supplemental Revenue Information, which is furnished pursuant to Item 7.01.

Exhibit 104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: Stephanie M. Kelly

/s/

M. Kelly

Securities and Governance Counsel, Corporate Secretary

Stephanie

Chief

Date: February 5, 2026

**Non-GAAP Financial Measures Included in the Financial Tables**

These revenue schedules include adjusted revenues and revenue growth rates on a currency-neutral, adjusted and organic basis. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD's underlying operational results or that affect period-to-period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our operating results and to understand future prospects.

Management uses these non-GAAP financial measures to measure and forecast the Company's performance, especially when comparing such results to prior periods or forecasts. We believe presenting such measures provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

We present revenue growth rates as compared to the corresponding prior periods on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We calculate foreign currency-neutral percentages by converting the current-period local currency financial results using the corresponding prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of revenues on a foreign currency-neutral basis in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to prior periods.

We present adjusted revenues for the full fiscal year 2024 and the third quarter of fiscal year 2024, excluding the recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, all of which substantially relate to years prior to fiscal year 2024, because we believe these items affect the comparability of the periods presented.

New BD refers to BD post the separation of the Biosciences and Diagnostic Solutions business from BD.

Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUE BY BUSINESS SEGMENTS AND UNITS  
 Twelve Months Ended September 30,  
 (Unaudited, \$ in millions)

	United States			International				Total					
				% Change							% Change		
	2025	2024	% Change	2025	2024	FX Impact	Reported	FXN	2025	2024	FX Impact	Reported	FXN
<b>Medical Essentials<sup>(1)</sup></b>													
Medication Delivery Solutions	\$ 2,789	\$ 2,661	4.8	\$ 1,787	\$ 1,768	\$ (7)	1.0	1.4	\$ 4,575	\$ 4,429	\$ (7)	3.3	3.5
Specimen Management	981	952	3.0	890	882	(2)	0.9	1.1	1,871	1,833	(2)	2.0	2.1
Total	\$ 3,770	\$ 3,612	4.4	\$ 2,676	\$ 2,650	\$ (9)	1.0	1.3	\$ 6,446	\$ 6,262	\$ (9)	2.9	3.1
<b>Connected Care<sup>(1)</sup></b>													
Medication Management Solutions	\$ 2,810	\$ 2,627	7.0	\$ 664	\$ 670	\$ 5	(1.0)	(1.7)	\$ 3,474	\$ 3,297	\$ 5	5.4	5.2
Advanced Patient Monitoring	658	47	NM	424	27	2	NM	NM	1,082	74	2	NM	NM
Total	\$ 3,469	\$ 2,674	29.7	\$ 1,088	\$ 697	\$ 7	56.0	55.0	\$ 4,556	\$ 3,371	\$ 7	35.2	34.9
BioPharma Systems <sup>(1)(2)</sup>	\$ 659	\$ 629	4.7	\$ 1,666	\$ 1,644	\$ 15	1.3	0.4	\$ 2,324	\$ 2,273	\$ 15	2.2	1.6
<b>Interventional<sup>(1)</sup></b>													
Peripheral Intervention	\$ 1,067	\$ 1,029	3.8	\$ 929	\$ 904	\$ 2	2.7	2.5	\$ 1,996	\$ 1,933	\$ 2	3.3	3.2
Urology and Critical Care	1,303	1,236	5.5	345	319	3	8.4	7.6	1,649	1,554	3	6.1	5.9
Surgery	1,175	1,130	4.0	397	363	2	9.5	8.9	1,572	1,492	2	5.3	5.2
Total	\$ 3,545	\$ 3,394	4.5	\$ 1,671	\$ 1,586	\$ 6	5.4	5.0	\$ 5,217	\$ 4,980	\$ 6	4.8	4.6
<b>Life Sciences<sup>(1)</sup></b>													
Diagnostic Solutions	\$ 755	\$ 782	(3.4)	\$ 1,083	\$ 1,064	\$ 5	1.8	1.4	\$ 1,838	\$ 1,846	\$ 5	(0.4)	(0.7)
Biosciences	593	577	2.8	865	935	6	(7.5)	(8.1)	1,458	1,512	6	(3.6)	(4.0)
Total	\$ 1,348	\$ 1,358	(0.8)	\$ 1,948	\$ 1,999	\$ 11	(2.6)	(3.1)	\$ 3,296	\$ 3,358	\$ 11	(1.8)	(2.2)
Other <sup>(3)</sup>	\$ —	\$ (6)	(100.0)	\$ —	\$ (62)	\$ —	(100.0)	(100.0)	\$ —	\$ (67)	\$ —	(100.0)	(100.0)
Total Revenues	\$12,790	\$11,663	9.7	\$ 9,049	\$ 8,515	\$ 30	6.3	5.9	\$21,840	\$20,178	\$ 30	8.2	8.1

"NM" denotes that the percentage change is not meaningful.

(1) Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the Company's product and service offerings. Prior period amounts have been recast to reflect the reorganization.

(2) The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

(3) Represents the recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, all of which substantially relate to years prior to fiscal year 2024. Such amounts were not allocated to our reportable segments.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 RECONCILIATION OF REPORTED REVENUE CHANGE TO ADJUSTED REVENUE CHANGE TO NEW BD ADJUSTED REVENUE  
 CHANGE AND ADJUSTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE TO NEW BD ORGANIC REVENUE CHANGE  
 Twelve Months Ended September 30,  
 (Unaudited, \$ in millions)

	2025	2024	FX Impact	% Change	
				Reported	FXN
Total Revenues	\$ 21,840	\$ 20,178	\$ 30	8.2	8.1
Add: Reduction for government legislative and legal matters <sup>(1)</sup>	—	67	—	(100.0)	(100.0)
Adjusted Total Revenues	\$ 21,840	\$ 20,245	\$ 30	7.9	7.7
Less: Life Sciences Segment Revenue	3,296	3,358	11	(1.8)	(2.2)
Total New BD Adjusted Revenue <sup>(2)</sup>	\$ 18,544	\$ 16,887	\$ 19	9.8	9.7
Adjusted Total Revenues	\$ 21,840	\$ 20,245	\$ 30	7.9	7.7
Less: Inorganic revenue adjustment <sup>(3)</sup>	977	—	1	NM	NM
Organic Revenue	\$ 20,863	\$ 20,245	\$ 28	3.1	2.9
Less: Life Sciences Segment Revenue	3,296	3,358	11	(1.8)	(2.2)
Total New BD Organic Revenue <sup>(4)</sup>	\$ 17,567	\$ 16,887	\$ 18	4.0	3.9
Connected Care Revenue	\$ 4,556	\$ 3,371	\$ 7	35.2	34.9
Less: Inorganic revenue adjustment <sup>(3)</sup>	977	—	1	NM	NM
Connected Care Organic Revenue	\$ 3,580	\$ 3,371	\$ 6	6.2	6.0

"NM" denotes that the percentage change is not meaningful.

- (1) Represents the recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to fiscal year 2024.
- (2) Total New BD Adjusted Revenue is inclusive of Adjusted Total Revenues attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
- (3) Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Acquisitions include: Advanced Patient Monitoring in the Connected Care segment.
- (4) Total New BD Organic Revenue is inclusive of Organic Revenue attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUE BY BUSINESS SEGMENTS AND UNITS  
 Three Months Ended September 30,  
 (Unaudited, \$ in millions)

	United States			International				Total					
			% Change			FX Impact	% Change				FX Impact	% Change	
	2025	2024		2025	2024		Reported	FXN	2025	2024		Reported	FXN
<b>Medical Essentials<sup>(1)</sup></b>													
Medication Delivery Solutions	\$ 728	\$ 689	5.7	\$ 474	\$ 458	\$ 12	3.5	0.9	\$ 1,202	\$ 1,147	\$ 12	4.8	3.8
Specimen Management	260	244	6.6	223	218	7	2.6	(0.5)	483	462	7	4.7	3.3
Total	\$ 988	\$ 933	5.9	\$ 697	\$ 676	\$ 19	3.2	0.4	\$ 1,686	\$ 1,609	\$ 19	4.8	3.6
<b>Connected Care<sup>(1)</sup></b>													
Medication Management Solutions	\$ 780	\$ 744	4.9	\$ 194	\$ 195	\$ 6	(0.4)	(3.8)	\$ 974	\$ 939	\$ 6	3.8	3.1
Advanced Patient Monitoring	169	47	NM	107	27	3	NM	NM	276	74	3	NM	NM
Total	\$ 949	\$ 791	20.0	\$ 301	\$ 222	\$ 10	35.7	31.3	\$ 1,250	\$ 1,013	\$ 10	23.4	22.5
BioPharma Systems <sup>(1)(2)</sup>	\$ 228	\$ 187	21.5	\$ 475	\$ 490	\$ 16	(3.1)	(6.3)	\$ 702	\$ 677	\$ 16	3.7	1.4
<b>Interventional<sup>(1)</sup></b>													
Peripheral Intervention	\$ 275	\$ 267	2.9	\$ 256	\$ 235	\$ 7	8.7	5.8	\$ 530	\$ 502	\$ 7	5.6	4.3
Urology and Critical Care	341	306	11.6	97	84	3	14.7	11.1	437	390	3	12.2	11.5
Surgery	290	279	4.0	110	89	3	22.6	18.9	400	368	3	8.5	7.6
Total	\$ 905	\$ 851	6.4	\$ 462	\$ 409	\$ 13	13.0	9.8	\$ 1,367	\$ 1,260	\$ 13	8.5	7.5
<b>Life Sciences<sup>(1)</sup></b>													
Diagnostic Solutions	\$ 199	\$ 204	(2.6)	\$ 300	\$ 277	\$ 10	8.2	4.5	\$ 498	\$ 481	\$ 10	3.6	1.5
Biosciences	153	151	1.5	234	247	8	(5.2)	(8.3)	387	397	8	(2.7)	(4.6)
Total	\$ 351	\$ 354	(0.8)	\$ 534	\$ 524	\$ 18	1.9	(1.5)	\$ 885	\$ 878	\$ 18	0.8	(1.2)
Total Revenues	\$ 3,422	\$ 3,117	9.8	\$ 2,468	\$ 2,320	\$ 75	6.4	3.2	\$ 5,890	\$ 5,437	\$ 75	8.3	7.0

"NM" denotes that the percentage change is not meaningful.

(1) Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the Company's product and service offerings. Prior period amounts have been recast to reflect the reorganization.

(2) The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO NEW BD REVENUE CHANGE AND REPORTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE TO NEW BD ORGANIC REVENUE CHANGE

Three Months Ended September 30,

(Unaudited, \$ in millions)

	2025	2024	FX Impact	% Change	
				Reported	FXN
Total Revenues	\$ 5,890	\$ 5,437	\$ 75	8.3	7.0
Less: Life Sciences Segment Revenue	885	878	18	0.8	(1.2)
<b>Total New BD Revenue <sup>(1)</sup></b>	<b>\$ 5,005</b>	<b>\$ 4,559</b>	<b>\$ 57</b>	<b>9.8</b>	<b>8.5</b>
 Total Revenues	 \$ 5,890	 \$ 5,437	 \$ 75	 8.3	 7.0
Less: Inorganic revenue adjustment <sup>(2)</sup>	170	—	3	NM	NM
<b>Organic Revenue</b>	<b>\$ 5,720</b>	<b>\$ 5,437</b>	<b>\$ 72</b>	<b>5.2</b>	<b>3.9</b>
Less: Life Sciences Segment Revenue	885	878	18	0.8	(1.2)
<b>Total New BD Organic Revenue <sup>(3)</sup></b>	<b>\$ 4,835</b>	<b>\$ 4,559</b>	<b>\$ 54</b>	<b>6.1</b>	<b>4.9</b>
 Connected Care Revenue	 \$ 1,250	 \$ 1,013	 \$ 10	 23.4	 22.5
Less: Inorganic revenue adjustment <sup>(2)</sup>	170	—	3	NM	NM
<b>Connected Care Organic Revenue</b>	<b>\$ 1,079</b>	<b>\$ 1,013</b>	<b>\$ 7</b>	<b>6.6</b>	<b>5.9</b>

"NM" denotes that the percentage change is not meaningful.

- (1) Total New BD Revenue is inclusive of Total Revenues attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
- (2) Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Acquisitions include: Advanced Patient Monitoring in the Connected Care segment.
- (3) Total New BD Organic Revenue is inclusive of Organic Revenue attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUE BY BUSINESS SEGMENTS AND UNITS  
 Three Months Ended June 30,  
 (Unaudited, \$ in millions)

	United States			International			Total						
				% Change									
	2025	2024	% Change	2025	2024	FX Impact	Reported	FXN	2025	2024	FX Impact	Reported	FXN
<b>Medical Essentials<sup>(1)</sup></b>													
Medication Delivery Solutions	\$ 680	\$ 670	1.4	\$ 452	\$ 453	\$ 1	(0.1)	(0.3)	\$ 1,132	\$ 1,123	\$ 1	0.8	0.7
Specimen Management	240	239	0.8	230	228	1	0.7	0.3	470	467	1	0.7	0.6
Total	\$ 920	\$ 909	1.3	\$ 682	\$ 681	\$ 1	0.1	(0.1)	\$ 1,602	\$ 1,590	\$ 1	0.8	0.7
<b>Connected Care<sup>(1)</sup></b>													
Medication Management Solutions	\$ 709	\$ 680	4.3	\$ 179	\$ 160	\$ 3	11.4	9.6	\$ 888	\$ 840	\$ 3	5.7	5.3
Advanced Patient Monitoring	176	—	NM	102	—	2	NM	NM	278	—	2	NM	NM
Total	\$ 885	\$ 680	30.2	\$ 281	\$ 160	\$ 5	75.1	72.1	\$ 1,166	\$ 840	\$ 5	38.8	38.2
BioPharma Systems <sup>(1)(2)</sup>	\$ 178	\$ 158	13.2	\$ 451	\$ 437	\$ 6	3.1	1.7	\$ 629	\$ 594	\$ 6	5.8	4.8
<b>Interventional<sup>(1)</sup></b>													
Peripheral Intervention	\$ 271	\$ 263	2.9	\$ 241	\$ 225	\$ 1	7.0	6.4	\$ 512	\$ 488	\$ 1	4.8	4.5
Urology and Critical Care	334	297	12.4	88	78	2	12.7	10.8	422	375	2	12.5	12.1
Surgery	294	283	3.6	101	93	1	9.0	7.7	395	376	1	4.9	4.6
Total	\$ 898	\$ 844	6.5	\$ 430	\$ 396	\$ 4	8.6	7.6	\$ 1,328	\$ 1,240	\$ 4	7.2	6.8
<b>Life Sciences<sup>(1)</sup></b>													
Diagnostic Solutions	\$ 154	\$ 167	(7.4)	\$ 271	\$ 263	\$ 3	3.1	1.8	\$ 425	\$ 429	\$ 3	(1.0)	(1.8)
Biosciences	145	141	2.9	213	222	3	(4.1)	(5.6)	358	363	3	(1.3)	(2.3)
Total	\$ 299	\$ 307	(2.6)	\$ 484	\$ 485	\$ 7	(0.2)	(1.6)	\$ 784	\$ 793	\$ 7	(1.1)	(2.0)
Other <sup>(3)</sup>	\$ —	\$ (6)	(100.0)	\$ —	\$ (62)	\$ —	(100.0)	(100.0)	\$ —	\$ (67)	\$ —	(100.0)	(100.0)
Total Revenues	\$ 3,181	\$ 2,891	10.0	\$ 2,328	\$ 2,098	\$ 23	11.0	9.8	\$ 5,509	\$ 4,990	\$ 23	10.4	9.9

"NM" denotes that the percentage change is not meaningful.

(1) Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the Company's product and service offerings. Prior period amounts have been recast to reflect the reorganization.

(2) The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

(3) Represents the recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, all of which substantially relate to years prior to fiscal year 2024. Such amounts were not allocated to our reportable segments.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 RECONCILIATION OF REPORTED REVENUE CHANGE TO ADJUSTED REVENUE CHANGE TO NEW BD ADJUSTED REVENUE  
 CHANGE AND ADJUSTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE TO NEW BD ORGANIC REVENUE CHANGE  
 Three Months Ended June 30,  
 (Unaudited, \$ in millions)

	2025	2024	FX Impact	% Change	
				Reported	FXN
Total Revenues	\$ 5,509	\$ 4,990	\$ 23	10.4	9.9
Add: Reduction for government legislative and legal matters <sup>(1)</sup>	—	67	—	(100.0)	(100.0)
Adjusted Total Revenues	\$ 5,509	\$ 5,057	\$ 23	8.9	8.5
Less: Life Sciences Segment Revenue	784	793	7	(1.1)	(2.0)
Total New BD Adjusted Revenue <sup>(2)</sup>	\$ 4,726	\$ 4,264	\$ 17	10.8	10.4
Adjusted Total Revenues	\$ 5,509	\$ 5,057	\$ 23	8.9	8.5
Less: Inorganic revenue adjustment <sup>(3)</sup>	278	—	2	NM	NM
Organic Revenue	\$ 5,231	\$ 5,057	\$ 21	3.4	3.0
Less: Life Sciences Segment Revenue	784	793	7	(1.1)	(2.0)
Total New BD Organic Revenue <sup>(4)</sup>	\$ 4,448	\$ 4,264	\$ 15	4.3	4.0
Connected Care Revenue	\$ 1,166	\$ 840	\$ 5	38.8	38.2
Less: Inorganic revenue adjustment <sup>(3)</sup>	278	—	2	NM	NM
Connected Care Organic Revenue	\$ 888	\$ 840	\$ 3	5.7	5.3

"NM" denotes that the percentage change is not meaningful.

- (1) Represents the recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, all of which substantially relate to years prior to fiscal year 2024.
- (2) Total New BD Adjusted Revenue is inclusive of Adjusted Total Revenues attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
- (3) Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Acquisitions include: Advanced Patient Monitoring in the Connected Care segment.
- (4) Total New BD Organic Revenue is inclusive of Organic Revenue attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUE BY BUSINESS SEGMENTS AND UNITS  
 Three Months Ended March 31,  
 (Unaudited, \$ in millions)

	United States			International				Total					
			% Change			FX Impact	% Change				FX Impact	% Change	
	2025	2024		2025	2024		Reported	FXN	2025	2024		Reported	FXN
<b>Medical Essentials<sup>(1)</sup></b>													
Medication Delivery Solutions	\$ 687	\$ 662	3.7	\$ 430	\$ 445	\$ (20)	(3.3)	1.3	\$ 1,117	\$ 1,107	\$ (20)	0.9	2.8
Specimen Management	242	236	2.7	213	222	(9)	(4.1)	0.1	456	458	(9)	(0.6)	1.4
Total	\$ 929	\$ 898	3.5	\$ 643	\$ 667	\$ (30)	(3.5)	0.9	\$ 1,573	\$ 1,565	\$ (30)	0.5	2.4
<b>Connected Care<sup>(1)</sup></b>													
Medication Management Solutions	\$ 662	\$ 609	8.6	\$ 149	\$ 162	\$ (6)	(8.2)	(4.5)	\$ 811	\$ 772	\$ (6)	5.1	5.9
Advanced Patient Monitoring	155	—	NM	102	—	(4)	NM	NM	257	—	(4)	NM	NM
Total	\$ 817	\$ 609	34.1	\$ 251	\$ 162	\$ (10)	54.6	60.7	\$ 1,068	\$ 772	\$ (10)	38.4	39.7
BioPharma Systems <sup>(1)(2)</sup>	\$ 149	\$ 157	(5.1)	\$ 426	\$ 413	\$ (7)	3.2	5.0	\$ 575	\$ 570	\$ (7)	0.9	2.2
<b>Interventional<sup>(1)</sup></b>													
Peripheral Intervention	\$ 269	\$ 264	1.9	\$ 212	\$ 225	\$ (8)	(5.5)	(1.9)	\$ 481	\$ 489	\$ (8)	(1.5)	0.1
Urology and Critical Care	323	347	(6.8)	77	78	(3)	(1.3)	2.6	400	424	(3)	(5.8)	(5.1)
Surgery	289	287	0.5	94	92	(3)	2.5	6.1	383	379	(3)	1.0	1.9
Total	\$ 880	\$ 898	(1.9)	\$ 384	\$ 395	\$ (14)	(2.8)	0.8	\$ 1,264	\$ 1,292	\$ (14)	(2.2)	(1.1)
<b>Life Sciences<sup>(1)</sup></b>													
Diagnostic Solutions	\$ 189	\$ 201	(5.8)	\$ 250	\$ 267	\$ (9)	(6.3)	(2.8)	\$ 440	\$ 468	\$ (9)	(6.1)	(4.1)
Biosciences	142	142	0.2	209	235	(7)	(10.7)	(7.9)	352	377	(7)	(6.6)	(4.8)
Total	\$ 332	\$ 343	(3.3)	\$ 460	\$ 502	\$ (16)	(8.4)	(5.2)	\$ 792	\$ 845	\$ (16)	(6.3)	(4.4)
Total Revenues	\$ 3,108	\$ 2,906	7.0	\$ 2,164	\$ 2,139	\$ (78)	1.2	4.8	\$ 5,272	\$ 5,045	\$ (78)	4.5	6.0

"NM" denotes that the percentage change is not meaningful.

(1) Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the Company's product and service offerings. Prior period amounts have been recast to reflect the reorganization.

(2) The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO NEW BD REVENUE CHANGE AND REPORTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE TO NEW BD ORGANIC REVENUE CHANGE

Three Months Ended March 31,

(Unaudited, \$ in millions)

	2025	2024	FX Impact	Reported	% Change
				FXN	
Total Revenues	\$ 5,272	\$ 5,045	\$ (78)	4.5	6.0
Less: Life Sciences Segment Revenue	792	845	(16)	(6.3)	(4.4)
<b>Total New BD Revenue <sup>(1)</sup></b>	<b>\$ 4,480</b>	<b>\$ 4,200</b>	<b>\$ (61)</b>	<b>6.7</b>	<b>8.1</b>
Total Revenues	\$ 5,272	\$ 5,045	\$ (78)	4.5	6.0
Less: Inorganic revenue adjustment <sup>(2)</sup>	257	—	(4)	NM	NM
Organic Revenue	\$ 5,015	\$ 5,045	\$ (74)	(0.6)	0.9
Less: Life Sciences Segment Revenue	792	845	(16)	(6.3)	(4.4)
<b>Total New BD Organic Revenue <sup>(3)</sup></b>	<b>\$ 4,223</b>	<b>\$ 4,200</b>	<b>\$ (57)</b>	<b>0.6</b>	<b>1.9</b>
Connected Care Revenue	\$ 1,068	\$ 772	\$ (10)	38.4	39.7
Less: Inorganic revenue adjustment <sup>(2)</sup>	257	—	(4)	NM	NM
Connected Care Organic Revenue	\$ 811	\$ 772	\$ (6)	5.1	5.9

"NM" denotes that the percentage change is not meaningful.

- (1) Total New BD Revenue is inclusive of Total Revenues attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
- (2) Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Acquisitions include: Advanced Patient Monitoring in the Connected Care segment.
- (3) Total New BD Organic Revenue is inclusive of Organic Revenue attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.

BECTON DICKINSON AND COMPANY  
 SUPPLEMENTAL REVENUE INFORMATION  
 REVENUE BY BUSINESS SEGMENTS AND UNITS  
 Three Months Ended December 31,  
 (Unaudited, \$ in millions)

	United States			International				Total				% Change	
			% Change				% Change		FX Impact		Reported	% Change	
	2024	2023		2024	2023	FX Impact	Reported	FXN		2024	2023	Reported	
<b>Medical Essentials<sup>(1)</sup></b>													
Medication Delivery Solutions	\$ 694	\$ 639	8.6	\$ 430	\$ 413	\$ 1	4.3	4.1	\$ 1,124	\$ 1,052	\$ 1	6.9	6.8
Specimen Management	238	234	2.0	223	213	—	4.8	4.7	462	447	—	3.3	3.3
Total	\$ 932	\$ 873	6.8	\$ 654	\$ 626	\$ 1	4.4	4.3	\$ 1,586	\$ 1,498	\$ 1	5.8	5.8
<b>Connected Care<sup>(1)</sup></b>													
Medication Management Solutions	\$ 659	\$ 594	11.0	\$ 142	\$ 153	\$ 2	(6.9)	(8.2)	\$ 801	\$ 747	\$ 2	7.3	7.1
Advanced Patient Monitoring	159	—	NM	113	—	1	NM	NM	271	—	1	NM	NM
Total	\$ 818	\$ 594	37.7	\$ 255	\$ 153	\$ 3	67.0	65.3	\$ 1,073	\$ 747	\$ 3	43.7	43.3
BioPharma Systems <sup>(1)(2)</sup>	\$ 104	\$ 127	(18.5)	\$ 314	\$ 304	\$ —	3.2	3.2	\$ 418	\$ 431	\$ —	(3.2)	(3.2)
<b>Interventional<sup>(1)</sup></b>													
Peripheral Intervention	\$ 253	\$ 234	7.8	\$ 220	\$ 220	\$ 1	0.2	(0.4)	\$ 473	\$ 454	\$ 1	4.1	3.8
Urology and Critical Care	306	287	6.6	83	78	1	6.8	5.4	389	365	1	6.6	6.3
Surgery	303	280	8.0	92	88	1	4.1	2.9	395	369	1	7.0	6.8
Total	\$ 861	\$ 802	7.4	\$ 396	\$ 386	\$ 4	2.4	1.5	\$ 1,257	\$ 1,188	\$ 4	5.8	5.5
<b>Life Sciences<sup>(1)</sup></b>													
Diagnostic Solutions	\$ 212	\$ 210	1.0	\$ 262	\$ 256	\$ 1	2.2	1.9	\$ 474	\$ 467	\$ 1	1.7	1.5
Biosciences	153	143	6.6	208	232	1	(10.1)	(10.7)	361	375	1	(3.7)	(4.1)
Total	\$ 365	\$ 354	3.3	\$ 470	\$ 488	\$ 2	(3.6)	(4.1)	\$ 836	\$ 842	\$ 2	(0.7)	(1.0)
Total Revenues	\$ 3,080	\$ 2,749	12.0	\$ 2,089	\$ 1,957	\$ 9	6.7	6.3	\$ 5,168	\$ 4,706	\$ 9	9.8	9.6

"NM" denotes that the percentage change is not meaningful.

(1) Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the Company's product and service offerings. Prior period amounts have been recast to reflect the reorganization.

(2) The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO NEW BD REVENUE CHANGE AND REPORTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE TO NEW BD ORGANIC REVENUE CHANGE

Three Months Ended December 31,

(Unaudited, \$ in millions)

	2024	2023	FX Impact	% Change	
				Reported	FXN
Total Revenues	\$ 5,168	\$ 4,706	\$ 9	9.8	9.6
Less: Life Sciences Segment Revenue	836	842	2	(0.7)	(1.0)
<b>Total New BD Revenue <sup>(1)</sup></b>	<b>\$ 4,333</b>	<b>\$ 3,864</b>	<b>\$ 7</b>	<b>12.1</b>	<b>11.9</b>
 Total Revenues	 \$ 5,168	 \$ 4,706	 \$ 9	 9.8	 9.6
Less: Inorganic revenue adjustment <sup>(2)</sup>	271	—	1	NM	NM
<b>Organic Revenue</b>	<b>\$ 4,897</b>	<b>\$ 4,706</b>	<b>\$ 8</b>	<b>4.1</b>	<b>3.9</b>
Less: Life Sciences Segment Revenue	836	842	2	(0.7)	(1.0)
<b>Total New BD Organic Revenue <sup>(3)</sup></b>	<b>\$ 4,062</b>	<b>\$ 3,864</b>	<b>\$ 6</b>	<b>5.1</b>	<b>4.9</b>
 Connected Care Revenue	 \$ 1,073	 \$ 747	 \$ 3	 43.7	 43.3
Less: Inorganic revenue adjustment <sup>(2)</sup>	271	—	1	NM	NM
<b>Connected Care Organic Revenue</b>	<b>\$ 801</b>	<b>\$ 747</b>	<b>\$ 2</b>	<b>7.3</b>	<b>7.1</b>

"NM" denotes that the percentage change is not meaningful.

- (1) Total New BD Revenue is inclusive of Total Revenues attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
- (2) Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition/divestiture. Acquisitions include: Advanced Patient Monitoring in the Connected Care segment.
- (3) Total New BD Organic Revenue is inclusive of Organic Revenue attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.